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Background. Dysphagia after stroke is common, associated independently with poor outcome, and has limited treatment options.
Pharyngeal electrical stimulation (PES) is a novel treatment being evaluated for treatment of poststroke dysphagia. Methods. We
searched electronically for randomised controlled trials of PES in dysphagic patients within 3 months of stroke. Individual patient
data were analysed using regression, adjusted for trial, age, severity, and baseline score. The coprimary outcomes were radiological
aspiration (penetration aspiration score, PAS) and clinical dysphagia (dysphagia severity rating scale, DSRS) at 2 weeks; secondary
outcomes included functional outcome, death, and length of stay in hospital. Results. Three completed trials were identified: 73
patients, age 72 (12) years, severity (NIHSS) 11 (6), DSRS 6.7 (4.3), mean PAS 4.3 (1.8). Compared with no/sham stimulation, PES
was associated with lower PAS, 3.4 (1.7) versus 4.1 (1.7), mean difference −0.9 (𝑝 = 0.020), and lower DSRS, 3.5 (3.8) versus 4.9 (4.4),
mean difference −1.7 (𝑝 = 0.040). Length of stay in hospital tended to be shorter: 50.2 (25.3) versus 71.2 (60.4) days (𝑝 = 0.11).
Functional outcome and death did not differ between treatment groups. Conclusions. PES was associated with less radiological
aspiration and clinical dysphagia and possibly reduced length of stay in hospital across three small trials.
1. Introduction
Stroke is the main cause of adult disability and the third
most common cause of death in Europe. Acute stroke is
complicated by oropharyngeal dysphagia in up to 50% of
patients and although it often resolves over the following
weeks, 40% of these patients can remain dysphagic a year
later [1]. Dysphagia leads to aspiration and a 3-fold increase
in pneumonia and malnutrition [2]. Patients who remain
chronically dysphagic require enteral feeding through a naso-
gastric tube (NG) or percutaneous endoscopically introduced
gastrostomy tube (PEG) and are more likely to require
long-term institutional care [3]. Although dysphagia may be
treated by a number of techniques, there are no definitive
interventions [4].
Human swallowing has bilateral representation in the
cerebral cortex but commonly with a dominant hemisphere
(which is unrelated to handedness) [5]. Dysphagia has been
shown to often follow a stroke that affects the dominant
cortex [6] or after a recurrent stroke. Importantly, swallow-
ing is highly dependent on afferent feedback from bulbar
cranial nerves innervating the upper aerodigestive tract
and a number of reports have demonstrated that increased
sensory input can drive long-term beneficial changes in the
cortical control of swallowing [7], and this is associated with
functionally relevant reorganisation of the swallowing cortex
[6, 7].
In normal volunteers and patients with subacute stroke
and dysphagia, pharyngeal electrical stimulation (PES) at
5Hz and 75% of maximum tolerated intensity (typically ∼10–
20mA) for 10 minutes produced the strongest effect on brain
excitability measured with transcranial magnetic stimulation
(TMS) [8]. Similar stimulation was able to completely reverse
a virtual lesion induced in the pharyngeal motor cortex
(by slow frequency repetitive TMS) in healthy subjects [8].
A similar treatment paradigm was also most effective in
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dysphagic patients after stroke in a dose comparison study
[9]. In a sham-controlled randomised phase II trial, PES was
associated with a reduction in dysphagia, assessed using the
dysphagia severity rating scale (DSRS) (see below), aspira-
tion, and length of stay in hospital [9]. In a further phase II
randomised sham-controlled trial, PES was associated with
nonsignificant trends to less clinical dysphagia,more removal
of nasogastric tube, and a shorter length of stay. In all of these
studies, PES was safe and well tolerated [9, 10].
The aim of the present study was to assess the safety
and efficacy of PES on radiological aspiration and clinical
dysphagia using individual patient data from the completed
randomised controlled trials. Aggregation of data from all
available trials reduces the influence of any one study, better
defines the point estimates of effects, and reduces the range of
possible effect sizes. A secondary aim was to assess optimal
methods for analysing aspiration and dysphagia scores in
patients with stroke.
2. Methods
2.1. Ethics. The anonymised individual patients data come
from randomised controlled trials that each involved obtain-
ing approval from national and local research ethics commit-
tees and written informed consent from the patients or proxy
consent from a designated person (partner, close family,
or close friend), as appropriate. Hence, no research ethics
approval or specific consent was needed for this study.
2.2. Search for Trials. Completed randomised controlled
trials that investigated the effect of PES versus no/sham PES
in patients with recent stroke and dysphagia were sought with
searches (November 2014) of electronic databases including
Cochrane Library (issue 3 2014), EMBASE, MEDLINE, and
Science Citation Index (ISI Web of Science). Reference lists
from identified reviews and trial publications were also
checked for additional trials. When duplicate publications
were identified, data from the primary report were used.
Publications could be in any language.
2.3. Relevant Trials. Trials were included if they were pub-
lished, enrolled adults with ischaemic stroke or haemorrhagic
stroke within 90 days of onset, and involved the randomised
delivery of pharyngeal electrical stimulation versus con-
trol (sham or open-label) treatment. Studies were excluded
because they either were not a randomised controlled trial,
were ongoing, did not include patients with stroke, included
patients with ventilated or chronic stroke, or did not measure
relevant outcomes.
2.4. Outcomes. The primary outcome was radiological aspi-
ration as assessed using the 8-level ordinal penetration aspira-
tion score (PAS, by videofluoroscopy) at about 2 weeks after
randomisation. The PAS score ranges from 1 (material does
not enter the airway) to 8 (aspirationwithout either a reflexive
or conscious attempt to expel material) [13]. Aspiration was
defined as PAS >3 a priori; although this is different from
the definition of PAS >5 as used by Rosenbek and colleagues
[13], scores of 4–8 signify aspiration (PAS 6–8) or material
remaining at the level of the vocal folds (PAS 4 or 5). Clinical
dysphagia at 2 weeks was assessed using the dysphagia
severity rating scale (DSRS) [9], a derivative of the dysphagia
outcome and severity scale [14]. The DSRS ranges from 0
(normal fluids, normal diet, and eating independently) to 12
(no oral fluids, no oral feeding) [9]. Clinical dysphagia was
defined a priori as DSRS >3 and severe dysphagia as DSRS
>7.
Secondary outcomes included severity/impairment
(National Institutes of Health Stroke Scale, NIHSS [15]),
respiratory tract infection (including pneumonia, a key
complication of dysphagia), length of stay in hospital (a key
early health economic measure), and death.
2.5. Data Sharing. The chief investigator of each identified
study was approached to join the collaboration and share
individual patient data. Data were transferred electronically
in statistical programme or Excel file formats. Data were
then imported into a single database. Before analysing the
database as a whole, representative analyses were performed
for each trial to ensure that results matched those that had
been published.
2.6. Statistics. All analyses were by intention to treat. Since
death is a common outcome after stroke in patients with
dysphagia, and to avoidmissing an effect whereby a treatment
might improve dysphagia but be unsafe, an extreme value
was added to the outcome aspiration and dysphagia scores,
as is done routinely for the modified Rankin Scale (mRS)
measure of dependency after stroke where death is assigned
a value of 6 [16]; therefore on-treatment PES ranged from
1 to 9 (where death = 9) and DSRS ranged from 0 to 13
(death = 13).The primary analysis of PAS used themean score
across 6 boli; secondary analyses of PAS were also performed
to assist in determining which approach might be optimal
in future studies and these assessed mean score across 3
boli, the cumulative PAS score across 6 boli (as used in the
source trials [9, 10]), number of boli with a PAS score >3,
number of patients with any bolus >3, and worst PAS score
across all boli. The effect of PES on PAS (mean score across
6 boli) was assessed in prespecified subgroups including age,
sex, stroke syndrome [12], severity, severe dysphagia (DSRS
>7), aspiration (mean PAS >3), number of PAS scores >3,
trial, stroke type (ischaemic, intracerebral haemorrhage), and
stimulation current. The primary analysis of DSRS used the
mean of patients scores; secondary analysis assessed the
number of patients with DSRS score >3 and the number of
patients with DSRS score >7. The effect of PES on DSRS was
assessed in the same prespecified subgroups as used for PAS.
Statistical analyses used binary logistic regression, ordinal
logistic regression, multiple regression, with adjustment for
age, relevant baseline score, impairment (NIHSS), and trial;
unadjusted analyses were also performed for completeness
(where the analysis was only adjusted for trial). Data are
number (%),median [interquartile range], ormean (standard
deviation). Effect size is presented as odds ratio or mean
difference, with 95% confidence intervals (95% CI). Analyses
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Table 1: Design characteristics of completed trials of electrical pharyngeal stimulation in patients with recent stroke and dysphagia.
Trial Jayasekeran-1 [9] Jayasekeran-2 [9] Vasant [10]
Year 2010 2010 2014
Participants (𝑁) 10 28 35
Design Dose comparison Parallel group Parallel group
Countries 1 1 1
Sites 1 2 3
PES sessions 1–3 3 3
Number of patients with PAS† 10 28 13
Bias [11]
Random sequence Low risk Low risk Low risk
Allocation sequence Low risk Low risk Low risk
Blinding High risk High risk High risk
Blinding of participants Unclear risk Unclear risk Unclear risk
Blinding of outcome Low risk Low risk Low risk
Incomplete outcome data Low risk High risk High risk
Selective reporting Low risk Low risk Low risk
†At baseline and 2 weeks.
Equipment: All studies used a transnasal catheter (3.2mmdiameter; Gaeltec Ltd., Isle of Skye, UK); this was connected to a preamplifier (CED 1902; Cambridge
Electronic Design, Cambridge, UK) with signals processed (HumBug; Quest Scientific, North Vancouver, British Columbia, Canada) and recorded (Signal
software, CED) running on a personal computer.
Funding:
Jayasekeran et al. 2010 [9]: Health Foundation, Medical Research Council.
Vasant et al. 2014 [10]: National Institutes of Health Research, Research for Patient Benefit.
were performed using SAS version 9.3 and 𝑝 < 0.05 is
considered significant.
3. Results
3.1. Included Trials. Searches identified 22 studies of which 19
studies were excluded because they either were ongoing, did
not include relevant outcomes [8], or were not relevant for
other reasons (Supplemental Table I in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/429053).
Three completed and published trials were identified that
assessed PES in patients with recent stroke and dysphagia
(Supplemental Figure I); key design and protocol criteria
are given for these in Table 1. One study was a small single
centre phase II trial and used a dose comparison design [9];
only data from the group that were stimulated at 5Hz for 10
minutes over 3 days were included so that the stimulation
parameters match those used in the other trials; the control
group were used whereas data from active groups having
other stimulation paradigms were not included. The other
two trials were multicentre and parallel group in design
[9, 10]. In the latter study, 17 of 35 participants had a valid
VFS at baseline, and 14 had a valid VFS at 2 weeks [10].
All three studies were sponsored by an academic institution
(University of Manchester).
3.2. Enrolled Patients. Altogether, the three trials recruited
a total of 73 patients with 37 randomised to PES and
36 to no/sham PES (Table 2). The average age was 72.0
(11.8) years with 45 (61.6%) being male. Women had higher
point estimates for severity markers of stroke, aspiration,
and dysphagia than men but none of the differences were
significant: NIHSS: women 11.5 (6.3), men 10.0 (5.5) (𝑝 =
0.28); PAS: women 4.3 (1.6), men 4.2 (2.0) (𝑝 = 0.80);
DSRS: women 7.7 (4.3), men 6.2 (4.2) (𝑝 = 0.20). The mean
time from stroke admission to randomisation was 15.1 (8.5)
days.Thirty-six (49.3%) patients were taking food enterally at
enrolment. Sixty-nine (94.5%) of patients had an ischaemic
stroke; patients with ischaemic and haemorrhagic (ICH)
stroke did not differ in severity: NIHSS 10.4 (5.9) versus 12.5
(3.1), difference 2.1 (95% CI −3.9, +8.0), and 𝑝 = 0.50. The
mean PAS and DSRS were 4.3 (1.8) and 6.7 (4.3), respectively,
at baseline (Table 2).
3.3. Stimulation Levels. The mean threshold sensitivity was
11.4 (5.6)mA and treatment level was 16.8 (6.6)mA (Table 2).
3.4. Radiological Outcomes. In an adjusted analysis, patients
randomised to PES had a significantly lower mean PAS score
at 2weeks by 0.9 points (of 9 points) than those assigned to no
PES (Table 3); the effect of PESwas consistent across the three
trials (Supplemental Table II, Figure 1) Significant reductions
in PASwere also seenwhen assessed using alternative analysis
approaches: mean of the first 3 scores (difference 0.9 points),
cumulative score across 6 boli (difference 6.0 points), and
number of boli scoring >3 (Table 3). A trend to a lower
worst bolus PAS score (i.e., worst PAS score across all boli)
was also seen with PES and in unadjusted analyses using all
statistical approaches. The effect of PES on mean PAS was
assessed in prespecified subgroups (Figure 2); interactions
were significant or had a trend (i.e., 𝑝 < 0.1) for markers
of stroke and dysphagia severity including baseline DSRS >7,
TACS syndrome, and NIHSS >10; in each case, PES appeared
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Table 2: Baseline characteristics of participants. Data are number (%), median [interquartile range], or mean (standard deviation).
Trial All PES No PES Trial 1 [9] Trial 2 [9] Trial 3 [10]
Participants (𝑁) 73 37 36 10 28 35
Age (years, mean, SD) 72.0 (11.8) 71.3 (13.4) 72.8 (9.9) 73.3 (11.9) 74.9 (9.7) 69.4 (12.9)
Sex (male, %) 45 (61.6) 24 (64.9) 21 (58.3) 5 (50.0) 19 (67.9) 21 (60.0)
mRS (/6) 3.0 (1.7) 𝑛 = 43 3.1 (1.7) 𝑛 = 21 2.9 (1.7) 𝑛 = 22 0.1 (0.4) 𝑛 = 8 NR 3.6 (1.0)
Stroke syndrome (%) [12]
TACS 34 (46.6) 19 (51.4) 15 (41.7) 3 (30.0) 10 (35.7) 21 (60.0)
PACS 33 (45.2) 16 (43.2) 17 (47.2) 5 (50.0) 16 (57.1) 12 (34.3)
LACS 4 (5.5) 2 (5.4) 2 (5.6) 2 (20.0) 1 (3.6) 1 (2.9)
POCS 2 (2.7) 0 (0) 2 (5.6) 0 (0) 1 (3.6) 1 (2.9)
Type (%)
Ischaemic 69 (94.5) 35 (94.6) 34 (94.4) 10 (100) 26 (92.9) 33 (94.3)
ICH 4 (5.5) 2 (5.4) 2 (5.6) 0 (0) 2 (7.1) 2 (5.7)
Severity, NIHSS (/42) 10.6 (5.8) 10.2 (5.9) 10.9 (5.8) 5.4 (4.2) 9.7 (4.1) 12.7 (6.4)
Side of lesion (%)
Normal 12 (32.4) 𝑛 = 37 7 (38.9) 𝑛 = 18 5 (26.3) 𝑛 = 19 5 (50.0) — 7 (25.9) 𝑛 = 27
Left 6 (16.2) 3 (16.7) 3 (15.8) 1 (10.0) — 5 (18.5)
Right 15 (40.5) 6 (33.3) 9 (47.4) 4 (40.0) — 11 (40.7)
Bilateral 4 (10.8) 2 (11.2) 2 (10.5) 0 (0) — 4 (14.8)
Feeding, enteral (%) 36 (49.3) 18 (48.6) 18 (50.0) 2 (20.0) 11 (39.3) 23 (65.7)
DSRS (/12) 6.7 (4.3) 𝑛 = 63 7.1 (4.2) 𝑛 = 33 6.3 (4.4) 𝑛 = 30 — 6.0 (4.8) 7.3 (3.8)
Median [IQR] 6.0 [9.0] 𝑛 = 63 8.0 [8.0] 𝑛 = 33 5.5 [9.0] 𝑛 = 30 — 5.5 [10.5] 7.0 [8.0]
= 12 (%) 17 (27.0) 𝑛 = 63 9 (27.3) 𝑛 = 33 8 (26.7) 𝑛 = 30 — 7 (25.0) 10 (28.6)
Weight (kg) 76.9 (23.6) 𝑛 = 41 75.2 (24.8) 𝑛 = 20 78.5 (22.9) 𝑛 = 21 78.0 (24.8) 𝑛 = 6 — 76.7 (23.8)
PAS (/8) 4.3 (1.8) 𝑛 = 60 4.6 (2.0) 𝑛 = 32 3.9 (1.6) 𝑛 = 28 4.5 (0.8) 4.3 (1.9) 4.2 (2.2) 𝑛 = 22
Mean of first 3 4.3 (2.2) 𝑛 = 60 4.7 (2.5) 𝑛 = 32 3.9 (1.8) 𝑛 = 28 4.9 (1.8) 4.1 (2.1) 4.3 (2.5) 𝑛 = 22
Number of boli >3 3.2 (2.1) 𝑛 = 60 3.6 (2.2) 𝑛 = 32 2.7 (2.0) 𝑛 = 28 3.5 (1.5) 3.4 (2.3) 2.6 (2.1) 𝑛 = 22
Any bolus >3 (%) 51 (85.0) 𝑛 = 60 28 (87.5) 𝑛 = 32 23 (82.1) 𝑛 = 28 9 (90.0) 23 (82.1) 19 (86.4) 𝑛 = 22
Worst [median, IQR] 7.0 [3.0] 𝑛 = 60 7.5 [3.0] 𝑛 = 32 6.0 [3.5] 𝑛 = 28 8.0 [3.0] 7.0 [3.0] 6.0 [3.0] 𝑛 = 22
Cumulative [/48] 25.0 [14.5] 𝑛 = 56 28.1 [17.0] 𝑛 = 30 23.5 [11.0] 𝑛 = 26 27.0 [5.0] 26.1 [16.0] 20.5 [19] 𝑛 = 18
TAR (days) 15.1 (8.5) 14.8 (8.5) 15.5 (8.7) 13.2 (7.3) 15.0 (7.7) 15.8 (9.6)
Electrical current (mA)
Sensitivity 11.4 (5.6) 𝑛 = 59 10.4 (5.3) 𝑛 = 33 12.8 (5.8) 𝑛 = 26 7.9 (3.2) 𝑛 = 4 10.3 (4.4) 𝑛 = 26 12.9 (6.4) 𝑛 = 29
Treatment 16.8 (6.6) 𝑛 = 56 15.5 (5.7) 𝑛 = 30 18.4 (7.2) 𝑛 = 26 12.3 (4.3) 𝑛 = 4 15.3 (5.2) 𝑛 = 23 18.6 (7.3) 𝑛 = 29
DSRS: dysphagia severity rating scale; ICH: intracerebral haemorrhage; LACS: lacunar syndrome; mRS: modified Rankin Scale; NIHSS: National Institutes of
Health Stroke Scale; NR: not recorded; PACS: partial anterior circulation syndrome; PAS: penetration aspiration score; POCS; posterior circulation syndrome;
SD: standard deviation; TACS: total anterior circulation syndrome; TAR: time admission-randomisation.
to be effective in patients defined as being more severe. PES
also appeared to be effective in patients who were sensitive
to low stimulation currents. The effect of PES on PAS did not
differ between the three trials (Figure 2).
3.5. Clinical Outcomes. Mean DSRS score was lower by 1.7
points (of 13 points) in patients randomised to PES versus
no PES (Table 3) at 2 weeks; the effect of PES was consistent
across the two trials that measured DSRS (Supplemental
Table II, Figure 3). Additionally, the proportion of patients
with clinical (functional) dysphagia at 2 weeks (DSRS>3) was
lower in the group randomised to PES. The effect of PES on
DSRS was assessed in prespecified subgroups (Supplemental
Figure II); a significant interaction for treatment current
was present with PES being more effective in patients who
received 10–20mA of stimulation. No differences in death,
impairment (National Institutes of Health Stroke Scale), or
respiratory tract infection (chest infection or pneumonia)
were seen between the two groups. Patients randomised to
PES tended to have a lower length of stay than those assigned
to no PES (Table 3, Supplemental Figure III).
4. Discussion
Dysphagia is a common complication after stroke and is
associated, independently, with a poor outcome. Although
there are a number of interventions that show promise for
treating dysphagia, none have definitive data [4]. Three trials
have now been reported assessing the safety and efficacy of
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Table 3: Comparison of outcomes at 2 weeks and discharge from hospital in 73 patients across three trials by treatment assignment
(pharyngeal electrical stimulation versus sham/placebo). Data are number (%), median [interquartile range], or mean (standard deviation).
Comparison by binary logistic regression (BLR), ordinal logistic regression (OLR), or multiple regression (MR), with 95% confidence
intervals. Adjustment: full model is adjusted for trial, relevant baseline score, age, and impairment (NIHSS); partial model is adjusted for
trial only.
Trials/patients PES Sham Difference/oddsratio (95% CI) 2𝑝
Difference/odds
ratio (95% CI) 2𝑝
Statistical model 37 36 Adjusted, full Adjustment, trial
2 weeks
PAS (/8) 3/55 3.4 (1.7) 4.1 (1.7)
−0.9 (−1.7, −0.1) 0.020 −0.7 (−1.6, 0.2) 0.13
Mean of first three 3/55 3.2 (1.7) 3.9 (1.9)
−0.9 (−1.7, 0.0) 0.044 −0.6 (−1.5, 0.3) 0.19
Cumulative (/48) 3/54 19.3 (9.6) 24.4 (10.4)
−6.0 (−10.7, −1.4) 0.011 −4.7 (−9.8, 0.5) 0.078
Number of boli >3 3/55 2.2 (2.1) 3.3 (2.0)
−1.4 (−2.2, −0.6) <0.001 −1.0 (−2.1, 0.0) 0.055
Any bolus >3 (%) 3/55 22 (75.9) 24 (92.3) 0.05 (0, 0.96) 0.047 0.26 (0.05, 1.49) 0.13
Worst [/8] 3/55 5 [2] 6 [3] 0.37 (0.11, 1.18) 0.092 0.7 (0.27, 1.81) 0.46
DSRS (/12) 2/63 3.5 (3.8) 4.9 (4.4)
−1.7 (−3.2, −0.1) 0.040 −1.3 (−3.3, 0.7) 0.19
Score >3 (%) 2/63 10 (30.3) 16 (53.33) 0.25 (0.07, 0.89) 0.032 0.39 (0.14, 1.10) 0.075
Score >7 (%) 2/63 6 (18.2) 7 (23.3) 0.54 (0.12, 2.36) 0.41 0.79 (0.23, 2.78) 0.71
NIHSS (/42) 2/44 7.9 (5.6) 9.1 (8.5) 0.4 (−2.5, 3.4) 0.77 −1.1 (−5.2, 3.1) 0.62
Died (%) 1/35 0 (0) 1 (5.6) — — — —
RTI (%) 2/63 4 (12.1) 4 (13.3) — — 0.83 (0.18, 3.74) 0.81
Discharge
Hospital stay (days) 3/73 50.2 (25.3) 71.2 (60.4)
−16.2 (−36.2, 3.7) 0.11 −18.5 (−39.0, 1.9) 0.075
Died, in hospital (%) 1/35 0 (0) 1 (5.6) — — — —
Died, end of trial (%) 1/35 1 (5.9) 1 (5.6) 1.2 (0.1, 25.8) 0.91 1.1 (0.1, 18.5) 0.97
Scores for death: DSRS = 13, NIHSS = 43, and PAS = 9.
DSRS: dysphagia severity rating scale; NIHSS: National Institutes of Health Stroke Scale; PAS: penetration aspiration score; RTI: respiratory tract infection
(chest infection or pneumonia).
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Figure 1: Box and whisker plot of change in penetration aspiration score from baseline to two weeks, by source trial. Comparison of
pharyngeal electrical stimulation (PES) versus no PES by multiple linear regression with adjustment, overall mean difference −0.9 (95%
confidence interval −1.7, −0.1; 𝑝 = 0.020); no difference between trials (𝑝 = 0.89).
PES in patients with recent (subacute) stroke and dysphagia.
In this individual patient data meta-analysis of data from
these trials, PES was associated with reduced aspiration on
videofluoroscopy (manifest as a lower penetration aspirations
score) and a reduced proportion of patients with clinical
dysphagia (defined as DSRS >3). Patients randomised to PES
also had a trend to a reduced length of stay in hospital. When
assessed in prespecified subgroups, PES appeared to be more
effective in reducing radiological aspiration in patients with
severe stroke, especially those with severe clinical dysphagia
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Age
≤70
>70
Sex
Female
Male
Stroke syndrome
TACS
Non-TACS
NIHSS
>10
≤10
DSRS
>7
≤7
Mean PAS score
≤4
Number of scores >3
No scores >3
1 or more scores >3
Stroke type
Ischaemic
ICH
Trial
Trial 1
Trial 2
Trial 3
Treatment mA
<10
10–20
>20
Sensitivity mA
<8
8–12
>12
Treatment-sensitivity
<3.5
≥3.5
Favours PES
−3 −1 1 3
Favours no PES
Subgroup analysis of mean PAS at 2 weeks
Mean difference and 95% confidence limits N 2p
0.63
28
45
0.22
28
45
0.097
34
39
0.017
33
40
0.005
29
34
0.29
29
31
0.26
9
51
0.92
69
4
0.89
10
28
35
0.15
8
32
16
0.005
16
21
22
0.2
17
39
>4
Figure 2: Mean penetration aspiration score, in subgroups: Age (≤70, >70), sex (female, male), stroke syndrome (non-TACS, TACS), stroke
severity (NIHSS ≤10, >10), stroke type (IS, ICH); DSRS (≤7, >7), mean PAS (≤4, >4), number PAS >3 (0, >0), trial (1, 2, and 3), treatment
current (<10, 10–20, and >20mA), sensitivity current (<8, 8–12, and >12mA), treatment-sensitivity current (<3.5, ≥3.5mA). Interaction tests
adjusted for trial, age, and baseline NIHSS and PAS.
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Figure 3: Box and whisker plot of change in dysphagia severity
rating scale (DSRS) from baseline to two weeks, by source trial.
Comparison of pharyngeal electrical stimulation (PES) versus no
PES by multiple linear regression with adjustment, overall mean
difference −1.7 (95% confidence interval −3.2, −0.1; 𝑝 = 0.040); no
difference between trials (𝑝 = 0.18).
(DSRS >7), and in patients who were sensitive to low
stimulation currents.
A number of interventions involving electrical stimula-
tion have been tested in the rehabilitation of patients with
stroke, including excitation of the vagus nerve, neck muscu-
lature (neuromuscular electrical stimulation) [17], pharynx
(as here), sphenopalatine ganglion [18], and cranium (via
transcranial direct current stimulation) [19]. In respect of
dysphagia, electrical stimulation is thought to induce func-
tional reorganisation of the swallowing cortex [7, 8] and this
mechanism may explain the positive findings seen for PES
with less aspiration and dysphagia. The observation that PES
might be most effective in patients with severe dysphagia
is plausible pathophysiologically and might allow treatment
to be focused on patients who are more likely to respond.
However, this observation is based on small numbers and
needs replication.That PESmight be associatedwith a shorter
length of stay is encouraging from a health economic point
of view and is likely to reflect less aspiration and dysphagia.
The finding that low treatment levels of PES aremost effective
is counter-intuitive and needs confirmation in other studies;
nevertheless, it may reflect that the pharynx is more sensitive
and that this is a marker of potential recovery.
The optimal methods for analysing PAS and DSRS scores
are unclear and a secondary aim of the present study was to
test various statistical approaches. Mean PAS and the number
of boli with PAS >3 were both statistically significant. Simi-
larly, DSRS was significant when analysed both as continuous
data and as the presence of clinical dysphagia (DSRS >3).
Although binary outcomes are easier to explain to patients
and healthcare staff, analyses using continuous or ordinal raw
data are usually more efficient statistically, as seen previously
for the mRS [20]. For both PAS and DSRS, analyses adjusted
for baseline prognostic factors should be more sensitive to
treatment change than those without adjustment, again as
seen previously for the mRS [21].
The present systematic review and meta-analysis has a
number of strengths. First, it used individual patient data
(IPD) from the trials rather than summary/group data.
Analyses based on IPD are considered to be the gold standard
[22] and allow subgroup analyses to be performed, as done
here. Second, data for all three identified and completed trials
of PES were available thereby removing any bias through
noninclusion of data. Third, aggregation of all available trials
reduces the influence of any one study, better defines the point
estimates of effects, and reduces the range of possible effect
sizes.
Nevertheless, several caveats are present. First, the avail-
able data are small (3 trials, 73 patients) so the conclusions
must be considered provisional. An ongoing larger study
(STEPS trial), which will be twice this size of this analysis,
will extend information on PES for poststroke dyspha-
gia. Although other studies of PES have been performed,
for example, in patients with stroke requiring ventilation,
chronic stroke, and multiple sclerosis [23–25], there is no
evidence that trials in acute and subacute stroke, as assessed
here, were missed. Second, the trials were not double-blind
although outcomes were assessed blinded to treatment; this
design aspect is common in trials of medical devices and is
difficult to overcome [26]. Third, although the mean baseline
aspiration severity, as measured using the PAS, was relatively
mild (mean 4.3), the PAS for the median worst swallow
was 7 suggesting most patients were aspirating during VFS.
Fourth, VFS might not be the optimal method for assessing
aspiration (swallow results are variable both within and
between boli, and patients with very severe stroke cannot
participate in the process) and use of flexible endoscopic
evaluation of swallowing (FEES) or even clinical judgment
(as done here with the DSRS) might be preferable. Fifth,
the size of effect seen with PES (improvements in PAS of
0.9 and DSRS 1.7) needs to be justified as being clinically
important; both represent a >10% improvement in score, and
both are associated with changes from severe to moderate,
moderate to mild, or mild to no aspiration/dysphagia. Last,
in two of the trials [9], PAS and DSRS were only measured at
2 weeks so that the effects of PES on longer-term aspiration
and dysphagia are not clear and need to be studied in future
trials.
In summary, PES appeared to reduce radiological aspi-
ration and clinical dysphagia in patients with poststroke
dysphagia, in three small trials. Larger trials are now needed
to confirm these findings.
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